‘Compulsory licence’ to Natco will bring down cost of cancer drug by 97%
The central government in a historic decision, allowed Indian company Natco Pharma to manufacture Sorafenib, a replicated version of pharma giant Bayer’s patented anti-cancer drug Nexavar. This is the...
View ArticleClik here to view.
Compulsory licensing effect: Cipla slashes price of generic cancer drug by 80%!
Cipla, one of the biggest Indian pharmaceutical companies today announced that they have reduced the price of the generic drug, Soranib from Rs 28,000 to Rs 6,840, a decrease of almost 80%. This move...
View ArticleClik here to view.
Bayer challenges ‘compulsory license’ ruling
Bayer AG isn’t going to take the compulsory licensing verdict lying down. In March, the Indian Patent Office, in a game-changing ruling allowed Natco, an Indian firm to replicate Bayer’s blockbuster...
View ArticleClik here to view.
Cipla to continue slashing cancer drug prices
When Cipla, the second largest pharma company in India, announced that it is slashing prices of three anti-cancer drugs used to treat brain, lung and kidney cancer it sent shockwaves in the pharma...
View ArticleClik here to view.
Intellectual property board hears Bayer vs compulsory licencing case, verdict...
The Intellectual Property Appellate Board (IPAB) in Chennai has concluded the hearing of Bayer’s appeal against the Indian Patent Office’s compulsory licencing case. The German drug giant had appealed...
View ArticleClik here to view.
India vs Big Pharma: Bayer loses compulsory licencing verdict
Compulsory licences are here to stay. The Intellectual Property Appellate Board (IPAB) on Monday upheld the country’s first compulsory licence to the Hyderabad based NATCO Pharma for Bayer’s cancer...
View ArticleClik here to view.
‘Compulsory licence verdict a triumph for humanity’
In what has been billed as landmark ruling the Intellectual Property Appellate Board upheld the country’s first compulsory licence to NATCO Pharma for Bayer’s cancer drug Nexavar recently. In layman...
View ArticleLeading lawyer calls India’s pharma sector ‘hip and hapenning’
India is a hip and happening country when it comes to litigations in the pharmaceutical and biotechnology sectors, said a leading patent attorney said on Thursday. I can definitely say that India is a...
View ArticleClik here to view.
India vs Big Pharma: Compulsory licence for leukaemia drug sought
That the compulsory licence verdict in favour of NATCO Pharma would change the landscape of the pharma industries the world over was never in doubt. The verdict was hailed as ‘revolutionary’,...
View ArticleNovartis not optimistic about Supreme Court verdict
It s a bad time for Big Pharma in India. First the Intellectual Property Appellate Board upheld the first ever compulsory licence handed out to NATCO to sell Bayer s blockbuster cancer drug Nexavar,...
View Article
